Neuroplast is highly experienced within the regenerative medicine arena, dedicated to the development and exploitation of an autologous bone marrow-derived Stem Cell platform denoted AMARCELL. The company's proprietary platform is optimally suited for the treatment of neurodegenerative diseases and disorders or severe ischemic diseases. Neuroplast has a leading position in the field of regenerative medicine and as a technology and support-providing partner we contribute in creating European Regions of Excellence for cell-based therapies throughout Europe.